PLTR

News:


 * Citing "improving visibility into near- and long-term growth," Goldman Sachs upgrades Palantir (NYSE:PLTR) from Neutral to Buy and ups the price target from $13 to $34. - Feb 17, 2021


 * October 1st, 2020: U.S. Army Research Lab Selects Palantir Technologies Inc. for $91M Artificial Intelligence and Machine Learning Development.
 * October 2nd, 2020: Palantir Technologies bags $36M IDIQ contract.
 * October 22, 2020: Palantir providing U.S. government with coronavirus tracking software. (Author's estimate: $5M)
 * November 18th, 2020: Palantir shares climb after announcing new U.S. Army contract. (Author's estimate: $5M)
 * December 7th, 2020: Palantir stock jumps +12% on report of new FDA contract. The contract, to power drug review and inspections, is worth $44.4M, Bloomberg says.
 * December 21st, 2020: Palantir receives $114M one-year option for U.S. Army's Vantage program.
 * December 23rd, 2020: Palantir inks 2-year contract for U.K. health services work worth $31.5M.


 * Growing along with margins. From the Q3 2020 call:

Turning to the third quarter, revenue grew 52% year-over-year, driven by continued expansion within our install base and initial wins at net new 2020 customers. We are distributing our platforms more efficiently than ever as we generated adjusted gross margins of 81% and contribution margin of 56% in the third quarter.


 * Lastly, the PLTR lock-up period expires at the end of next week. (Feb 19, 2021)
 * https://seekingalpha.com/article/4406054-palantir-potential-q4-revenue-blowout?mail_subject=pltr-palantir-potential-q4-revenue-blowout&utm_campaign=rta-stock-article&utm_content=link-0&utm_medium=email&utm_source=seeking_alpha


 * 2020 Q4： Revenue was up 40% on the year to $322.1M. The loss per share totaled $0.08 versus the positive $0.02 consensus.
 * Palantir shares are down 5.6% pre-market.
 * For the year, revenue increased 47% to $1.1B. Average revenue per customer was up 41% to $7.9B. Average revenue from top 20 customers was up 34% to $33.2M.
 * New Q4 contracts included Rio Tinto, PG&E, BP, U.S. Army, U.S. Air Force, FDA, and NHS. There were 21 total contracts signed that each had a total contract value of $5M or more. Twelve contracts were worth $10M or more.